Travere Therapeutics (TVTX)
NASDAQ:TVTX
Want to see TVTX full AI Analyst Report?
TVTX Stock Chart & Stats
$39.54
-$0.11(-0.58%)
At close: 4:00 PM EST
$39.54
-$0.11(-0.58%)
Day’s Range― - ―
52-Week Range$13.88 - $43.31
Previous CloseN/A
Volume140.04K
Average Volume (3M)1.81M
Market Cap
$3.78B
Enterprise Value$3.89B
Total Cash (Recent Filing)$322.80M
Total Debt (Recent Filing)$339.87M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Apr 30, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding92,241,550
10 Day Avg. Volume3,067,209
30 Day Avg. Volume1,812,667
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)29.69
Price to Sales (P/S)6.95
P/FCF Ratio90.22
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue7.94
Enterprise Value/Gross Profit8.42
Enterprise Value/Ebitda175.25
Forecast
1Y Price Target
$48.45Price Target Upside22.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.29
Revenue Forecast (FY)$694.67M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And KOL SupportAnalyses tying proteinuria reduction to slower kidney decline, along with key opinion leader enthusiasm, suggest meaningful clinical benefit that could accelerate adoption among nephrologists.
Commercial ExpansionExpanded label that includes pediatric patients and overlap with physicians treating IgA nephropathy, combined with a larger sales team and a stronger-than-expected IgA nephropathy launch, broadens the drug's commercial reach and uptake potential.
Regulatory ApprovalFDA approval of Filspari as the first therapy approved for focal segmental glomerulosclerosis without nephrotic syndrome validates efficacy in a defined patient subgroup and reduces regulatory uncertainty around proteinuria as an endpoint.
Bears Say
Clinical Efficacy UncertaintyMixed DUPLEX trial results and kidney function trends favoring irbesartan raise doubts about the drug's comparative benefit and could limit physician willingness to prescribe.
Label LimitationsInitial exclusion of patients with active nephrotic syndrome and variability in the supporting dataset shrink the immediate eligible population and introduce uncertainty about long-term treatment durability.
Pricing And Revenue PressureExpectations of larger gross-to-net discounts point to potential reductions in net product revenue, which could weigh on financial results even if demand increases.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $13.88 and its highest was $43.31 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $3.78B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 12 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Feb 19, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.002 by $0.028.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 92,241,550 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of $0.03 in its last earnings report, beating expectations of $0.002. Following the earnings report the stock price went up 3.72%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.45 (22.53% Upside)
$48.45 (22.53% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.64%
12-Months-Change
Fundamentals
Return on Equity
-79.16%
Trailing 12-Months
Asset Growth
1.86%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
TVTX Company Deck
TVTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum for FILSPARI with record demand, significant year-over-year revenue growth (FILSPARI +144% FY2025) and improved profitability/non-GAAP earnings, supported by a solid cash position and tangible pipeline progress (FSGS sNDA under review and pegtibatinase Phase III reactivation). Offsetting risks include an FDA information-request-driven delay to the FSGS PDUFA date, materially higher SG&A and rising gross-to-net discounts that will modestly compress near-term revenue and margins, and the emergence of new competitive entrants in IgAN. Overall, the positive operational and financial developments outweigh the challenges, but the regulatory timing and higher investment profile warrant continued monitoring.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$48.45
▲(22.53% Upside)
Technical Analysis
Galapagos
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
1.56% Insiders
36.86% Mutual Funds
0.18% Other Institutional Investors
45.30% Public Companies and
Individual Investors